Immunome Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
11. Segment information
The Company hasone operating and reportable segment related to the development of targeted oncology therapies. The segment has historically derived its revenues from research and development collaborations.
The CODM assesses performance for the segment based on net loss, which is reported on the condensed consolidated statements of operations and comprehensive loss as net loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets. When evaluating the Company’s financial performance, the CODM regularly reviews total revenues, total expenses and research and development expenses by program.
The table below is a summary of the segment net loss, including significant segment expense categories (in thousands):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Collaboration revenue | $— | $— | $— | $6,941 |
| Less: | ||||
| Direct research and development expenses(1) | ||||
| Varegacestat | 12,579 | 12,495 | 33,128 | 39,615 |
| IM-1021 | 9,578 | 2,874 | 19,789 | 7,669 |
| IM-1617 | 1,629 | 5,465 | 4,496 | 9,397 |
| IM-1340 | 1,725 | 3,322 | 7,261 | 4,811 |
| IM-3050 | 2,229 | 2,104 | 5,092 | 4,149 |
| Other direct research and development | 13,265 | 6,404 | 31,565 | 15,081 |
| Indirect research and development(2) | 21,062 | 13,143 | 57,768 | 36,593 |
| General and administrative(3) | 14,530 | 6,997 | 36,652 | 21,246 |
| Other segment expenses(4) | 13,765 | 7,334 | 32,077 | 19,632 |
| Total operating expenses | 90,362 | 60,138 | 227,828 | 158,193 |
| Loss from operations | (90,362) | (60,138) | (227,828) | (151,252) |
| Interest income | 4,579 | 2,681 | 15,079 | 8,758 |
| Net loss | (85,783) | $(57,457) | $(212,749) | $(142,494) |
(1)
Direct research and development expenses include external costs, such as costs related to laboratory materials and services, manufacturing, outsourced research, product development, and clinical trial costs, including fees paid to investigators, consultants, central laboratories and CROs for specific product candidates.
(2)
Indirect research and development expenses include certain overhead expenses, and personnel salary and benefit costs, excluding share-based compensation costs.
(3)
General and administrative expenses include legal fees, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel, certain overhead expenses and personnel salary and benefit costs, excluding share-based compensation.
(4)
Other segment expenses include non-cash share-based compensation costs and depreciation and amortization.
For the three and nine months ended September 30, 2026, the Company revised the presentation of its significant segment expense categories to align with how the CODM currently evaluates the Company's financial performance. Prior period amounts have been reclassified to conform to the current year presentation.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.